Efalizumab;Efalizumab

Annales de Dermatologie et de Venereologie

Volumn 133, Issue 8-9, 2006, Pages 666-678

  Descamps, V ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN PRESENTING CELL; ARTHRALGIA; ASTHENIA; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DYSPNEA; EDEMA; ENDOTHELIUM CELL; FLU LIKE SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; INFLUENZA; KERATINOCYTE; LABORATORY TEST; LONG TERM CARE; LYMPHOCYTE MIGRATION; LYMPHOCYTOSIS; MEMORY T LYMPHOCYTE; MYALGIA; NAUSEA; PHOTOTHERAPY; PRESCRIPTION; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT WITHDRAWAL; VOMITING;

EID: 33748752604     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(06)70989-9     Document Type: Article

References (40)

1. Davignon D, Martz E, Reynolds T, Kurzinger K, Springer TA. Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing. Proc Natl Acad Sci USA 1981;78:4535-9.
2. Sanchez-Madrid F, Krensky AM, Ware CF, Robbins E, Strominger JL, Burakoff SJ, et al. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA 1982;79:7489-93.
3. Qi SY, Groves JT, Chakraborty AK. Synaptic pattern formation during cellular recognition. Proc Natl Acad Sci USA 2001;98:6548-53.
4. Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, Shaw AS. T cell receptor signaling precedes immunological synapse formation. Science 2002;295:1539-42.
5. Andrew DP, Spellberg JP, Takimoto H, Schmits R, Mak TW, Zukowski MM. Transendothelial migration and trafficking of leukocytes in LFA-1-deficient mice. Eur J Immunol 1998;28:1959-69.
6. Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 2004;113:38-46.
7. Wulfing C, Sjaastad MD, Davis MM. Visualizing the dynamics of T cell activation: intracellular adhesion molecule 1 migrates rapidly to the T cell/B cell interface and acts to sustain calcium levels. Proc Natl Acad Sci USA 1998;95:6302-7.
8. Perez OD, Mitchell D, Jager GC, South S, Murriel C, McBride J, et al. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol 2003;4:1083-92.
9. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
10. Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004;310:896-904.
11. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005;45:286-98.
12. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006;6:27-36.
13. Cavazzana-Calvo M, Bordigoni P, Michel G, Esperou H, Souillet G, Leblanc T, et al. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle Osseuse. Br J Haematol 1996;93:131-8.
14. Le Mauff B, Hourmant M, Rougier JP, Hirn M, Dantal J, Baatard R, et al. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991;52:291-6.
15. Hourmant M, Bedrossian J, Durand D, Lebranchu Y, Renoult E, Caudrelier P, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996;62:1565-70.
16. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, HotalingT, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986-95.
17. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002;2:898-903.
18. Gauvreau GM, Becker AB, Boulet LP, Chakir J, Fick RB, Greene WL, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003;112:331-8.
19. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.
20. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliveer WP, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001;45:665-74.
21. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
22. Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003;7:198-207.
23. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
24. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80.
25. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.
26. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-33.
27. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, et al. Clinical Experience Acquired with Raptiva® (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international placebo controlled trial. Br J Dermatol 2006;155:170-81.
28. Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54:S1154-63.
29. Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:S164-70.
30. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004;3:27-38.
31. Ortonne JP, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomised, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial. BMC Dermatology 2005;5:13.
32. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
33. Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, et al. Safety of efalizumab in patients with moderate to sever chronic plaque psoriasis: Review of Clinical Data. Part II. J Cutan Med Surg 2006 (sous presse). Published on line 25 may 2006.
34. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005;141:82-4.
35. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006;54:5171-81.
36. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209.
37. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005;27:1317-28.
38. Warkentin TE, Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 2005;143:761-3.
39. Berthelot C, Cather J, Jones D, Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006;6:329-32.
40. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006;54:S182-8.